LGD-4033 and Meldonium Interaction

Monitor
Mechanism-based 51% confidence

LGD-4033 and Meldonium have an interaction requiring monitoring for interaction with 51% confidence. Both LGD-4033 and Meldonium can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Meldonium

Metabolic Modulator | Endurance & Cardioprotection

Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time.

Half-life: ~4-6 hours Typical dose: 500-1000 mg/day cardiovascular, metabolic
epo receptor blood pressure raisingcardiotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate
Pancreas
low

Shared Safety Flags

2x 2 compounds raise blood pressure (LGD-4033, Meldonium). Monitor BP daily and consider cardiovascular support.
2x 2 compounds disrupt lipids (LGD-4033, Meldonium). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Meldonium). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Meldonium?

Yes, but with caution. Both LGD-4033 and Meldonium can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.

Is LGD-4033 and Meldonium safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between LGD-4033 and Meldonium?

Both LGD-4033 and Meldonium can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Meldonium?

LGD-4033 has a half-life of ~24-36 hours and Meldonium has a half-life of ~4-6 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Meldonium

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.